Please use this identifier to cite or link to this item: https://doi.org/10.1101/gad.1819009
Title: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A
Authors: Xiaojing, Y.
Min, F.
Xia, J.
Zhenlong, W.
Zhimei, L.
Meiyee, A.
Qiang, Y. 
Keywords: CDC25A
CDK6
DZNep
E2F1
miR-449
Issue Date: 15-Oct-2009
Citation: Xiaojing, Y., Min, F., Xia, J., Zhenlong, W., Zhimei, L., Meiyee, A., Qiang, Y. (2009-10-15). miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes and Development 23 (20) : 2388-2393. ScholarBank@NUS Repository. https://doi.org/10.1101/gad.1819009
Abstract: The Rb-E2F pathway drives cell cycle progression and cell proliferation, and the molecular strategies safeguarding its activity are not fully understood. Here we report that E2F1 directly transactivates miR-449a/b. miR-449a/b targets and inhibits oncogenic CDK6 and CDC25A, resulting in pRb dephosphorylation and cell cycle arrest at G1 phase, revealing a negative feedback regulation of the pRb-E2F1 pathway. Moreover, miR-449a/b expression in cancer cells is epigenetically repressed through histone H3 Lys27 trimethylation, and epigenetic drug treatment targeting histone methylation results in strong induction of miR-449a/b. Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer. © 2009 by Cold Spring Harbor Laboratory Press.
Source Title: Genes and Development
URI: http://scholarbank.nus.edu.sg/handle/10635/113218
ISSN: 08909369
DOI: 10.1101/gad.1819009
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.